X hits on this document

PDF document

Wednesday April 07, 2010 - 10:45 AM EDT - page 1 / 4

37 views

0 shares

0 downloads

0 comments

1 / 4

Teva to Present New Data on Multiple Sclerosis and Parkinson’s Disease at the 62nd American Academy of Neurology Annual Meeting

Wednesday April 07, 2010 - 10:45 AM EDT

Source: Business Wire News Releases Author: Teva Pharmaceutical Industries Ltd.

Click here to read the original story

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies supporting the company's innovative central nervous system (CNS) portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

Featured presentations highlight:

  • Pre-clinical data surrounding the unique mechanism of action (MOA) of Copaxone® (glatiramer acetate injection), further demonstrating how the product works with the immune system. Additional data underscoring the benefit-risk profile of Copaxone®, the global market-leading relapsing-remitting multiple sclerosis (RRMS) treatment, in both treatment-naive and pre-treated patients.

  • An analysis of placebo patients from the ADAGIO study of Azilect® (rasagiline tablets) in Parkinson's disease (PD), providing information on the natural progression of clinical symptoms of the disease in its early stages. The subgroup analyses provide further insight into the larger effect size seen for rasagiline in ADAGIO patients with greater severity of disease at baseline.

  • Pre-clinical and early animal model data demonstrating the immunomodulatory and potential neuroprotective properties of Teva's investigational, once-daily, oral laquinimod. These data provide further insight into the novel MOA of laquinimod, which is currently being investigated for the treatment of RRMS in two global Phase III clinical trials.

  • The innovative study design of the OCTAGON (Optical Coherence Tomography Assessment of Glatiramer acetate On retinal Nerve fiber layer) trial exploring the use of glatiramer acetate in the early treatment of Acute Optic Neuritis

  • Results demonstrating the potential role and impact of Neutralizing Antibody (NAb) Testing on multiple sclerosis (MS) treatment decisions

Platform Presentations/Poster Sessions

Copaxone®

  • [P04.223] Glatiramer Acetate-Reactive T Lymphocytes Regulate Oligodendrocyte Progenitor Cell Number In Vitro (Poster Session IV: MYueting Zhang, Farzaneh Jalili, Nadia Oumara, Andleeb Zameer, Gregory Cosentino, Liat Hayardeny, Jack Antel, Amit Bar-Or, Gareth John

  • [PD5.003] Glatiramer Acetate Immunomodulates Pro-Inflammatory B Cell Function in Central Nervous System Autoimmune Disease (Poster Discussion Session V: MDeetje Hertzenberg, Martina Betz, Klaus Lehmann-Horn, Scott Zamvil, Patrice Lalive D'Epinay, Bernhard Hemmer, Martin Weber

  • [P06.138] Short-Term Immunosuppression with Mitoxantrone Followed by Long-Term Glatiramer Acetate vs Glatiramer Acetate Alone: Results at 60 Months in Patients with Relapsing Multiple Sclerosis (Poster Session VI: MTimothy Vollmer, Amit Bar-Or, Denise Campagnolo, Hillel Panitch, Douglas Arnold

1

Document info
Document views37
Page views40
Page last viewedSun Dec 04 06:21:04 UTC 2016
Pages4
Paragraphs68
Words1702

Comments